


**Product Name** : WJ-39  
**Cat. No.** : PC-22474  
**CAS No.** : 3009908-95-3  
**Molecular Formula** : C<sub>19</sub>H<sub>14</sub>Cl<sub>2</sub>KNO<sub>4</sub>  
**Molecular Weight** : 430.32  
**Target** : Aldose Reductase  
**Solubility** : 10 mM in DMSO



## Biological Activity

WJ-39 (Darirestat potassium salt) is a small molecule aldose reductase (AR) inhibitor, does not affect AR protein expression, reduces oxidative stress by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway.

WJ-39 treatment ameliorated streptozotocin- (STZ-) induced renal inflammation in diabetic nephropathy (DN) rats.

WJ-39 suppressed the activation of the nuclear factor-kappa B (NF-κB) pathway and the nucleotide-binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome to reduce the secretion of inflammatory factors.

WJ-39 alleviated inflammation via the Nrf2 pathway in rat mesangial cells cultured under high glucose (HG) conditions.

WJ-39 treatment prevented renal fibrosis by suppressing the TGF-β1/Smad pathway in diabetic nephropathy (DN).

WJ-39 reduced oxidative stress in the kidneys of DN rats by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway.

WJ-39 ameliorates renal tubular injury in diabetic nephropathy by activating PINK1/Parkin signaling.

## References

Yang L, et al. Eur J Pharmacol. 2024 Mar 15;967:176376.

Zhou X, et al. Oxid Med Cell Longev. 2020 May 30;2020:7950457.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com